CN115381841B - 一种异石胆酸的用途 - Google Patents
一种异石胆酸的用途 Download PDFInfo
- Publication number
- CN115381841B CN115381841B CN202210971125.3A CN202210971125A CN115381841B CN 115381841 B CN115381841 B CN 115381841B CN 202210971125 A CN202210971125 A CN 202210971125A CN 115381841 B CN115381841 B CN 115381841B
- Authority
- CN
- China
- Prior art keywords
- lithocholic acid
- streptococcus mitis
- application
- test
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 title claims abstract description 18
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 title claims abstract description 17
- 241001134658 Streptococcus mitis Species 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- SMEROWZSTRWXGI-WFVDQZAMSA-N isolithocholic acid Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-WFVDQZAMSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 208000001050 sialadenitis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开一种已知化合物―异石胆酸的用途，即在制备抗缓症链球菌ATCC49456药物中的应用。本发明首次发现了异石胆酸具有抑制缓症链球菌ATCC49456的活性，实验表明异石胆酸具有良好的抑制缓症链球菌ATCC49456的活性，是一种潜在的可代替现有抗生素抑制缓症链球菌ATCC49456的药物。
Description
技术领域
本发明涉及一种已知化合物―异石胆酸的用途。
背景技术
胆汁酸是胆汁里的一个有效成分，是参与胆汁消化功能的重要成分之一。其含量变化在肝脏病诊断中具有重要的参考价值，已公开的文献中披露胆汁酸具有抑制肿瘤的效果。另，中国发明专利申请202111019726.6公开胆石酸具有抗金葡菌MRSA和MSSA、大肠埃希菌Esbls+、大肠埃希菌Esbls-和铜绿假单胞菌的抑菌活性。异石酸分子式为C24H40O3,结构式如下：
发明内容
本发明涉及异石胆酸的一种用途，即在制备抗缓症链球菌ATCC49456药物中的应用。
缓症链球菌属于α-溶血性链球菌(亦称甲型溶血性链球菌)，通常是人体口腔、消化道、生殖道等部位的正常菌群之一，该菌是一种条件致病菌，可致中毒性休克综合征，亚急性心内膜炎，前列腺炎等，此外，还可致肺炎、心包炎、腹膜炎、唾腺炎、口面部感染、牙源性感染、中耳炎、鼻窦炎等。据报道在发病猪体内分离到此病原菌，并且导致仔猪发病和死亡严重，说明缓症链球菌对猪也是有致病性。在儿科常用抗生素中，缓症链球菌对氨曲南、头孢曲松、哌拉西林/他唑巴坦、阿莫西林/克拉维酸钾均有不同程度耐药，耐药率达到42.3％-48.1％。这些抗生素目前仍然是儿童肺炎的常用药物。细菌耐药是全球问题，但相应的抗生素的开发则进展缓慢，形式非常严峻，因此迫切需要一种新的抗菌药物或抗菌产品来抑制细菌。
本发明首次发现了异石胆酸具有抑制缓症链球菌ATCC49456的活性，实验表明异石胆酸具有良好的抑制缓症链球菌ATCC49456的活性，是一种潜在的可代替现有抗生素抑制缓症链球菌ATCC49456的药物。
附图说明
图1：异石胆酸浓度与缓症链球菌生长抑制率关系图。
图2：氯霉素浓度与缓症链球菌生长抑制率关系图。
具体实施方式
本发明以下结合相关实验详细说明，实验中采用微量肉汤二倍稀释法对异石胆酸进行了体外抗菌活性测试，考察其对缓症链球菌的抗菌活性，以对照品氯霉素进行实验系统的评价。
(一)供试品及对照
1.1供试品
名称：异石胆酸，市售商品
供试品临用前用乙醇配制成最大浓度16.67mg/mL，依次对倍稀释。
1.2对照品
名称：氯霉素，市售品。
(二)测试菌株及其培养方法
2.1菌株：缓症链球菌ATCC49456
2.2菌种来源：购于北京百欧博伟生物技术有限公司。
2.3培养条件：Todd-Hewitt Broth，37℃孵育24h-48h。
2.4菌种开启接种并培养
用75％酒精棉擦拭西林瓶外部，在安全柜内使用尖嘴钳去除塑料盖及铝盖。缓慢开启胶塞，用75％酒精棉消毒瓶口部分，使用无菌吸管注入0.5ml液体培养基复溶冻干粉末，将悬液接种在培养基上，37℃培养24小时后，挑取单个菌落于液体培养基中在相同的培养条件下培养增菌。
2.5菌液工作液的准备
当OD600值达到0.5左右(约108CFU/ml)，经THB肉汤梯度稀释(0、10、100、1000、10000、100000、10000倍)后，取100μL菌悬液接种于固体培养基上，培养24h后计数活菌数，计算菌悬液浓度，再将此混悬菌液进行稀释，使菌悬液最终浓度约为2×106CFU/ml。菌种操作均在无菌条件下进行，实验完毕，所有耗材经灭菌再做丢弃处理。
(三)抑制50％受试菌所需最低抑菌浓度的测定(MIC50)
3.1测试方法：采取微量肉汤稀释法，进行MIC50的测定。
实验分为阳性对照组(即不含药物的菌悬液)、阴性对照组(含溶媒乙醇的培养基)和实验组(含不同浓度的异石胆酸菌悬液)。以上各组均设置3个平行组。将浓度为100μg/ml的异石胆酸实验液按对倍稀释溶于液体培养基中，使其终浓度为100μg/ml、50μg/ml、25μg/ml、12.5μg/ml、6.25μg/ml、3.125μg/ml、1.5625μg/ml、0μg/ml。浓度为2×106CFU·mL-1菌悬液与各组药液按比例1∶1各100μL，分别接种于无菌96孔板中，使菌悬液的终浓度为1×106CFU/ml(含105CFU/孔)，置于适当的培养条件下培养20h。同时设置对照品氯霉素，使其终浓度分别为32μg/ml、16μg/ml、8μg/ml、4μg/ml、2μg/ml、1μg/ml、0μg/ml。培养结束后，在黑色背景下进行肉眼观察，平皿内未见细菌生长的最低药物浓度即为异石胆酸的最低抑菌浓度(MIC)。所有菌种的MIC测定实验重复3次。悬浮菌体测OD600值，不同浓度的供试品及对照抑菌率的计算方法：抑菌率(％)＝1-(供试品OD值—阴性对照OD值)/(阳性对照OD值—阴性对照OD值)×100％。通过曲线拟合得函数计算而得MIC50。
3.2结果判断
本次试验结果见表1，抑制率图见图1。当阳性对照孔(即不含药物)内细菌明显生长，试验才有意义。结果显示，阳性对照孔(即不含药物)内细菌正常生长，溶媒对照培养基孔无菌生长。对照品氯霉素对缓症链球菌的MIC值为4μg/ml，参见表2和图2，符合美国临床实验室标准化委员会(National committee for clinical library standardization,NCCLS)2001年的《抗微生物药物敏感试验的执行标准：第十一版信息增刊》M100-S11中氯霉素对缓症链球菌≤4μg/ml的标准，说明本实验方法是可靠的。
统计结果表明：异石胆酸对受试的缓症链球菌的MIC50为12.52μg/ml。综上所述，异石胆酸有良好的抑制缓症链球菌活性。
表1：不同浓度异石胆酸对缓症链球菌生长影响的吸光值测定
表2：不同浓度氯霉素对缓症链球菌生长影响的吸光值测定
Claims (1)
1.异石胆酸在制备抗缓症链球菌ATCC49456药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210971125.3A CN115381841B (zh) | 2022-08-11 | 2022-08-11 | 一种异石胆酸的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210971125.3A CN115381841B (zh) | 2022-08-11 | 2022-08-11 | 一种异石胆酸的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115381841A CN115381841A (zh) | 2022-11-25 |
| CN115381841B true CN115381841B (zh) | 2024-01-30 |
Family
ID=84118016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210971125.3A Active CN115381841B (zh) | 2022-08-11 | 2022-08-11 | 一种异石胆酸的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115381841B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202021595A (zh) * | 2018-08-10 | 2020-06-16 | 德商菲尼克斯製藥股份有限公司 | 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物 |
| CN113559013A (zh) * | 2021-09-01 | 2021-10-29 | 南充市中心医院 | 石胆酸类化合物在制备抗菌产品中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077123B2 (en) * | 2016-02-29 | 2021-08-03 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Use of bile acids and bile salts as anti bacterial agents for inhibition of bacterial conjugation and horizontal gene transfer |
-
2022
- 2022-08-11 CN CN202210971125.3A patent/CN115381841B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202021595A (zh) * | 2018-08-10 | 2020-06-16 | 德商菲尼克斯製藥股份有限公司 | 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物 |
| CN113559013A (zh) * | 2021-09-01 | 2021-10-29 | 南充市中心医院 | 石胆酸类化合物在制备抗菌产品中的应用 |
Non-Patent Citations (3)
| Title |
|---|
| Human gut bacteria produce ΤΗ17-modulating bile acid metabolites;Donggi Paik等;《Nature》;第603卷;第907-938页 * |
| The Role of Bile Acid in Improving Glucose Tolerance of Non-Obese Diabetic Rats After Proximal Small Bowel Bypass;Zhihua Zheng等;《Frontiers in Physiology》;第13卷;第1-10页 * |
| 不同性别C57BL/6 小鼠肠道胆汁酸组成的差异性研究;张聪聪等;《波谱学杂志》;第35卷(第3期);第328-337页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115381841A (zh) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davcheva-Chakar et al. | Adenoid vegetations–reservoir of bacteria for chronic otitis media with effusion and chronic rhinosinusitis | |
| Tel et al. | Investigation of the antibiotic resistance and biofilm formation of Staphylococcus aureus strains isolated from gangrenous mastitis of ewes | |
| CN113491692A (zh) | C-jun n末端激酶抑制剂su3327的用途 | |
| Crombleholme et al. | Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin | |
| Yerat et al. | A clinicomicrobial study of diabetic foot ulcer infections in South India | |
| Jalil et al. | Inhibitory activity of Mentha spicata oils on biofilms of Proteus mirabilis isolated from burns | |
| CN115381841B (zh) | 一种异石胆酸的用途 | |
| CN115350198B (zh) | 一种表别石胆酸的用途 | |
| CN115252627B (zh) | 一种石胆酸的用途 | |
| Ngu Ngwa et al. | Bacterial pathogens involved in bovine mastitis and their antibiotic resistance patterns in the Adamawa region of Cameroon | |
| Van Bijsterveld et al. | Fusidic acid in infections of the external eye | |
| Nedbalcová et al. | The determination of minimum inhibitory concentrations of selected antimicrobials for porcine Haemophilus parasuis isolates from the Czech Republic | |
| CN115364107B (zh) | 石胆酸的用途 | |
| CN115531394B (zh) | 脱氧胆酸在制备抗缓症链球菌的产品中的应用 | |
| Bodey et al. | PC-904, a new semisynthetic penicillin | |
| CN112353820B (zh) | 新型st型crpa菌株的应用 | |
| Salih et al. | Anti–biotypes of Different Bacteria Isolated from Different Clinical Sources | |
| Kotgire et al. | Aerobic bacteriological profile and its antimicrobial sensitivity pattern from blood culture specimens in a tertiary care hospital | |
| CN115569141B (zh) | 脱氧胆酸在制备抗口腔链球菌产品中的应用 | |
| Nikolova et al. | Studies on the causes of bacterial mastities in two dairy bovine farms in northeastern Bulgaria and their sensitivity to antimicrobial products. | |
| Kriukova et al. | Tiamulin fumarat–new makrolide on bovine mastitis therapy in vivo and in vitro | |
| Kumar et al. | Bacteriological profile and antibiogram of blood culture isolates of septicemic patients from neonatal and pediatric intensive care units | |
| CN115531395B (zh) | 脱氧胆酸在制备抗婴儿链球菌的产品中的应用 | |
| CN102462683B (zh) | 一种抗菌素组合物、其制备方法和用途 | |
| Madut et al. | Susceptibility of Corynebacterum spp. responsible for bovine mastits against commonly used antibiotics in Kuku dairy farms, Sudan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |